BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
SKB264: trial readouts and FDA decisions
3 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 4 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Klus Pharma Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06711900 A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients Wi | Non-Small Cell Lung Cancer | active not recruiting | 432 |
| 2026-12-30 est. | P2 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT05631262 SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors | Selected Subjects With Advanced Solid Tumors | active not recruiting | 321 |
| 2026-12-31 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06081959 Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer | Metastatic Breast Cancer | recruiting | 376 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06448312 A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | active not recruiting | 406 |
| 2026-08-31 | P2 | Klus Pharma Inc. | NCT05816252 A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003) | Non-small Cell Lung Cancer | active not recruiting | 356 |
| 2026-08 est. | P2 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT05351788 SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. | Non-small Cell Lung Cancer | recruiting | 110 |
| 2026-07-31 | P2 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT05445908 SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer | Triple-negative Breast Cancer and HR+/HER2- BC | completed | 184 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.